

SUPPORTING INFECTIOUS DISEASE RESEARCH

Product Information Sheet for NR-55406

Spike Glycoprotein N-Terminal Domain (NTD) from SARS-Related Coronavirus 2, N234Q Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells

Catalog No. NR-55406 ACROBiosystems Catalog No. S1D-C52H7

For research use only. Not for use in humans.

Contributor and Manufacturer:

ACROBiosystems, Newark, Delaware, USA

Product Description:

A recombinant form of the spike (S) glycoprotein N-terminal (NTD) domain from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), N234Q variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography.1 NR-55406 lacks the signal sequence, contains 291 residues of the SARS-CoV-2 S glycoprotein (amino acid residues S13 to L303) and features a C-terminal poly-histidine tag. NR-55406 is a variant of SARS-CoV-2 which contains the N234Q mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416).12 The predicted protein sequence is shown in Figure 1.1 NR-55406 has a theoretical molecular weight of 34,911 daltons. Representative SDS-PAGE results are shown in Figure 2.1

The S glycoprotein mediates viral binding to the host angiotensin-converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes.³ The N234Q mutation has been shown to have decreased sensitivity to some neutralizing monoclonal antibodies.⁴

Material Provided:

Each vial contains approximately 100 µg of purified recombinant protein lyophilized in a sterile phosphate-buffered saline, pH 7.4 and 10% trehalose.

Packaging/Storage:

NR-55406 was packaged aseptically in glass vials. The product is provided lyophilized and should be placed in a closed, dry environment with desiccants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect protein stability.

Functional Activity:

The biological activity of NR-55406 was measured by its binding ability in a functional ELISA (Figure 3), in which immobilized NR-55406 at 1 $\mu g/mL$ (100 $\mu L/well)$ can bind to Anti-SARS-CoV-2 Spike NTD Antibody, Chimeric mAb (ACROBiosystems Cat. No. SPD-M121); the linear range is 0.2 to 6 ng/mL.1

Reconstitution:

NR-55406 should be reconstituted with 167 μ L sterile deionized water to a stock solution of 600 μ g/mL. Add sterile deionized water at room temperature with occasional gentle mixing. To avoid surface adsorption loss and inactivation, the reconstituted protein must NOT be aliquoted to less than 10 ug per vial. Carrier protein [e.g. 0.1% (w/v) bovine serum albumin] must be included in the reconstitution buffer if the final protein concentration is lower than recommended or NR-55406 is aliquoted to less than 10 μ g per vial. Note: Avoid vigorous shaking or vortexing.

Storage of Reconstituted Protein:

Reconstituted NR-55406 should be stored at -70°C or colder immediately and used within 3 months. Avoid repeated freeze-thaw cycles.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein N-Terminal Domain (NTD) from SARS-Related Coronavirus 2, N234Q Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells, NR-55406."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

Product Information Sheet for NR-55406

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- 1. Chen, J., Personal Communication.
- Wu, F., et al. "A New Coronavirus Associated with Human Respiratory Disease in China." <u>Nature</u> 579 (2020): 265-269. PubMed: 32015508.
- Hulswit, R. J. G., C. A. M. de Haan and B. -J. Bosch. "Coronavirus Spike Protein and Tropism Changes." <u>Adv. Virus Res.</u> 96 (2016): 29-57. PubMed: 27712627.
- Li, Q; et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. <u>Cell.</u> 182 (2020):1284-1294. PubMed: 32730807.

ATCC[®] is a trademark of the American Type Culture Collection.

Figure 1: Predicted Protein Sequence

1	SQCVNLTTRT	QLPPAYTNSF	TRGVYYPDKV	FRSSVLHSTQ	DLFLPFFSNV
51	TWFHAIHVSG	TNGTKRFDNP	VLPFNDGVYF	ASTEKSNIIR	GWIFGTTLDS
101	KTQSLLIVNN	ATNVVIKVCE	FQFCNDPFLG	VYYHKNNKSW	MESEFRVYSS
151	ANNCTFEYVS	QPFLMDLEGK	QGNFKNLREF	VFKNIDGYFK	IYSKHTPINL
201	VRDLPQGFSA	LEPLVDLPIG	IQITRFQTLL	ALHRSYLTPG	DSSSGWTAGA
251	AAYYVGYLQP	RTFLLKYNEN	GTITDAVDCA	LDPLSETKCT	$\mathbf{L}GGGSGGGS\underline{H}$
301	нннннннн				_

S protein – Residues 1 to 291 [represents amino acid residues 13 to 303 of the native protein (GenPept: QHD43416)]

N234Q mutation – Residue 222 Linker – Residues 292 to 299 Poly-histidine tag – Residues 300 to 309

Figure 2: Representative SDS-PAGE





Figure 3: Representative ELISA



BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898